Ohm, I hope you are right (I think you are) :)
Post# of 155333
(Total Views: 492)
Posted On: 02/22/2020 6:28:24 PM
Ohm,
I hope you are right (I think you are)
This being the case, we are in to a few Billions of income !!. Below a copy-and-paste from an article (emphasis is mine).
Keytruda Set to Become World’s Top-Selling Drug, Forecast Shows
Published: Oct 04, 2019
While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, another drug is set to take the number-one position. With the continued regulatory wins, it should be no surprise that Merck’s Keytruda is poised to assume the best-selling drug mantle.
AbbVie’s Humira brought in more than $20 billion in revenue in 2018, making it the king-of-the-hill for global drug sales. But by 2023, Humira will have lost its patent protection in the United States and that revenue stream will begin to dwindle as new drugs will begin to chip away at its market share. For example, in November 2018, the U.S. Food and Drug Administration (FDA) approved Sandoz’ Hyrimoz, a biosimilar to Humira, but due to the patent protection, it cannot be launched in the U.S. until 2023.
Merck’s Keytruda (pembrolizumab), on the other hand, continues to rack up regulatory approvals and is proving to be the tent-pole therapy for Merck’s oncology pipeline. During an Investor’s Day conference in June, Merck's Chief Commercial Officer Frank Clyburn said in a short time, Keytruda has become a foundational cancer treatment. “We have activity across 25 different cancer types… and Keytruda is changing the way in which patients are being treated today,” Clyburn said at the time.
That significant activity in cancer is the reason Keytruda is projected to generate $22.5 billion in revenue by 2025, according to an analysis by GlobalData, a data and analytics company. Last year, Keytruda generated more than $7 billion in revenue and, based on the more than $5 billion it earned in the first half of 2019, could hit $10 billion or more by the end of this year. Keshalini Sabaratnam, a pharma analyst at GlobalData, said Keytruda has developed into Merck’s biggest product since it was first approved by the FDA in 2015
I hope you are right (I think you are)
This being the case, we are in to a few Billions of income !!. Below a copy-and-paste from an article (emphasis is mine).
Keytruda Set to Become World’s Top-Selling Drug, Forecast Shows
Published: Oct 04, 2019
While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, another drug is set to take the number-one position. With the continued regulatory wins, it should be no surprise that Merck’s Keytruda is poised to assume the best-selling drug mantle.
AbbVie’s Humira brought in more than $20 billion in revenue in 2018, making it the king-of-the-hill for global drug sales. But by 2023, Humira will have lost its patent protection in the United States and that revenue stream will begin to dwindle as new drugs will begin to chip away at its market share. For example, in November 2018, the U.S. Food and Drug Administration (FDA) approved Sandoz’ Hyrimoz, a biosimilar to Humira, but due to the patent protection, it cannot be launched in the U.S. until 2023.
Merck’s Keytruda (pembrolizumab), on the other hand, continues to rack up regulatory approvals and is proving to be the tent-pole therapy for Merck’s oncology pipeline. During an Investor’s Day conference in June, Merck's Chief Commercial Officer Frank Clyburn said in a short time, Keytruda has become a foundational cancer treatment. “We have activity across 25 different cancer types… and Keytruda is changing the way in which patients are being treated today,” Clyburn said at the time.
That significant activity in cancer is the reason Keytruda is projected to generate $22.5 billion in revenue by 2025, according to an analysis by GlobalData, a data and analytics company. Last year, Keytruda generated more than $7 billion in revenue and, based on the more than $5 billion it earned in the first half of 2019, could hit $10 billion or more by the end of this year. Keshalini Sabaratnam, a pharma analyst at GlobalData, said Keytruda has developed into Merck’s biggest product since it was first approved by the FDA in 2015
(3)
(0)